Biosearch Technologies, Inc.
Petaluma, CA LGC Biosearch Technologies
- UEI
- NX7NLJUNSEU6
- CAGE
- 1WZ85
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, KKR & Co. Inc., ranks #28 in NAICS 32519
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 2199 S McDowell Blvd Ext, Petaluma, CA 94954, USA
- Website
- biosearchtech.com
- Founded
- 1993
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $50,968 |
| FY2025 | $284,012 |
| FY2024 | $908,321 |
| FY2023 | $1,121,359 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of the Navy | $52,952 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| GMP influenza a primer kit | CDC Pittsburgh | $40,368 | |
| Laboratory reagents - primers | Bureau of Medicine and Surgery (Navy) | $52,952 | |
| Biosearch technologies - primers and probes | Bureau of Medicine and Surgery (Navy) | $51,129 | |
| PCR testing kits | CDC Pittsburgh | $249,997 | |
| GMP manufacturing of CDC FLUSC2 multiplex euaand IVD kits | CDC Pittsburgh | $763,453 |
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Technologies for the rapid engineering of bacterial chromosomes with synthetic DN | National Institutes of Health | $0 | |
| Azoreductase mediated fluorescence assays | National Institutes of Health | $311,038 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| I D T | Coralville, IA | 325199 All Other Basic Organic Chemical Manufacturing |
| Twist Bioscience Corporation | South San Francisco, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Takara Bio Usa, Inc. | San Jose, CA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Chapter Diagnostics Inc. | Menlo Park, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Eurofins Genomics LLC | Louisville, KY | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Biosearch Technologies, Inc., operating as the LGC Biosearch Technologies Division and headquartered in Petaluma, California, manufactures oligonucleotide-based molecular biology tools, diagnostic reagents, and laboratory supplies for federal health and defense agencies exclusively as a prime contractor (100% of recent awards). The company is foreign-owned, for-profit, and competes on a full-and-open basis without SBA set-aside certifications, placing work across 181 federal prime awards with a combined potential value of $341.2 million and $26.3 million in combined dollars obligated to date.
Biosearch Technologies' customer concentration is heavily weighted toward the Department of Health and Human Services Centers for Disease Control and Prevention, which accounts for 99% of combined potential value across all awards. The CDC Office of Acquisition Services holds 34 awards valued at $272.4 million combined potential value, and CDC Pittsburgh holds 48 awards valued at $54.5 million, for a combined 82 awards representing approximately 326.9 million dollars across the two CDC entities. The Department of the Navy Bureau of Medicine and Surgery is the second-largest customer by award count with 21 awards, though the Navy relationship is modest at $460 thousand combined potential value. The Air Force Materiel Command Research Laboratory places 17 awards at $5.1 million combined potential value. Recent representative work includes a $763,453 definitive contract with CDC Pittsburgh for GMP manufacturing of FluSC2 Multiplex EUA and IVD diagnostic kits awarded September 2024, a $757,634 sole-source definitive contract with CDC for SARS-CoV-2 influenza multiplex oligonucleotide primers and probes awarded April 2023, a $249,997 purchase order from CDC Pittsburgh for PCR testing kits awarded November 2024, and a $52,952 purchase order from the Bureau of Medicine and Surgery for laboratory reagents-primers with performance in Peru awarded April 2026.
Biosearch Technologies holds vehicle positions that underpin its federal footprint. The company carries an indefinite delivery contract FA860113D0009 under the Air Force Materiel Command with 19 task orders valued at $851 thousand combined potential value, BPA 75D30119A04957 with the CDC carrying 15 task orders at $4.2 million combined potential value, and multiple CDC indefinite delivery contracts including HHSD200200826694I (12 task orders, $3.3 million), HHSD200201357252I (8 task orders, $3.1 million), and HHSD200200514645I (4 task orders, $4.4 million). A newly awarded single-award $9 million CDC BPA effective September 2026 with ultimate completion in November 2031 consolidates the vendor's position for PCR primer probes, dual-labeled probes, and diagnostic assay components for Laboratory Response Network distribution, with place of performance in Petaluma, California, Atlanta, Georgia, and Peru.
Work is categorized across biological product and in-vitro diagnostic substance manufacturing (NAICS 325414 and related codes represent 118 of 181 awards), with PSC coding concentrated on laboratory equipment and supplies (84 awards) and in vitro diagnostic substances, reagents, test kits and sets (49 awards). The vendor performs all manufacturing and fulfillment in-house with no subcontract footprint. Activity has declined year over year from three awards in 2023 to one in 2027, with minimal recompete exposure—only one award valued at $40 thousand completes in the next twenty-four months. First federal contract award dates to 2002, establishing a longstanding supplier relationship with CDC and military medical commands for pathogen detection, disease surveillance, and diagnostic testing components.
Quick answers
Is Biosearch Technologies, Inc. registered in SAM.gov?
Yes. Biosearch Technologies, Inc.'s SAM.gov registration is active through February 16, 2027.
How much has Biosearch Technologies, Inc. received in federal contracts?
Federal contracts obligated $284,012 to Biosearch Technologies, Inc. in fiscal year 2025 and $2,364,659 in fiscal years 2023 through 2027.
How does Biosearch Technologies, Inc. rank among federal contractors?
Biosearch Technologies, Inc.'s parent company, KKR & Co. Inc., ranked #28 in NAICS 32519 in FY2025.
What is Biosearch Technologies, Inc.'s most recent federal award?
Biosearch Technologies, Inc.'s most recent federal contract award is GMP influenza a primer kit (75D30126P20867), from CDC Pittsburgh, on February 27, 2027.
On GovTribe
See Biosearch Technologies, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors